Evidence map›Paper›PMID 38361799›Full record

ArticleHealth science reports2024

Global incidence of intrahepatic cholestasis of pregnancy: A protocol for systematic review and meta-analysis.

Alireza Sadeghi

Abstract read
In one paragraph

Article in Health science reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Bile acids as therapeutic agents.Frontiers in pharmacology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Alireza SadeghiStudent Research Committee Shiraz University of Medical Sciences Shiraz Iran.ORCID 0000-0002-7950-3270

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Intrahepatic cholestasis of pregnancy (ICP) typically develops in the late second and third trimesters and resolves rapidly after delivery. Although not associated with serious maternal sequelae, ICP can be highly bothersome. On the other hand, the major complications of ICP are fetal and neonatal, which can be fatal. The current knowledge lacks an estimation regarding the global prevalence of ICP. Methods: PubMed, Scopus, and Web of Science will be searched systematically. Records will be screened for eligibility by two independent reviewers. Observational studies that reported the incidence of ICP will be eligible. Joanna Bridge Institute checklist for appraisal of prevalence studies will be used for quality assessment. Freeman-Tukey double arcsine transformed effect sizes will be pooled under random-effect models. The residual between study heterogeneity will be quantified using Discussion: Estimating the global and regional prevalence of ICP and evaluating the effects of moderating factors will provide valuable insights into the knowledge. Further investigations on the moderating factors will help researchers to hypothesize the associations and extend the current understanding of the disease. The planned study will be the first systematic review and meta-analysis that estimates the global prevalence of ICP. The reviewers will try rigorous mythology to ensure high-quality evidence. However, substantial heterogeneity is expected as prevalence studies utilize different mythologies, settings, and definitions. Moreover, this study relies on utilizing previously published studies, which may impede the overall data quality and comprehensiveness.

Indexed as

intrahepatic cholestasismeta‐analysispregnancyprotocolsystematic review

Identifiers

PMID38361799
PMCPMC10867694

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.